The eIg technology to generate Ig-like bispecific antibodies

References

• Brinkmann U, Kontermann RE. Bispecific antibodies. Science. 2021;372(6545):916–13. PMID:34045345. doi:10.1126/science.abg1209.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Janmaat ML, Reichert JM, Pwhi P. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585–608. PMID:31175342. doi:10.1038/s41573-019-0028-1.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9(2):182–212. PMID:28071970. doi:10.1080/19420862.2016.1268307.
   PubMed Web of Science ®Google Scholar
• Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015;67(2):95–106. PMID:25637431. doi:10.1016/j.molimm.2015.01.003.
   PubMed Web of Science ®Google Scholar
• J-h H, Kim J-E, Kim Y-S. Immunoglobulin Fc heterodimer platform technology: from design to applications in therapeutic antibodies and proteins. Front Immunol. 2016;7:394. PMID:27766096. doi:10.3389/fimmu.2016.00394.
   PubMed Web of Science ®Google Scholar
• Krah S, Sellmann C, Rhiel L, Schröter C, Dickgiesser S, Beck J, Zielonka S, Toleikis L, Hock B, Kolmar H, et al. Engineering bispecific antibodies with defined chain pairing. N Biotechnol. 2017;39:167–73. PMID:28137467. doi:10.1016/j.nbt.2016.12.010.
   PubMed Web of Science ®Google Scholar
• Nie S, Wang Z, Moscoso-Castro M, D’Souza P, Lei C, Xu J, Gu J. Biology drives the discovery of bispecific antibodies as innovative therapeutics. Antib Ther. 2020;3(1):18–62. PMID:33928225. doi:10.1093/abt/tbaa003.
   PubMedGoogle Scholar
• Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A. 2011;108(27):11187–92. PMID:21690412. doi:10.1073/pnas.1019002108.
   PubMed Web of Science ®Google Scholar
• Seifert O, Plappert A, Fellermeier S, Siegemund M, Pfizenmaier K, Kontermann RE. Tetravalent antibody-scTRAIL fusion proteins with improved properties. Mol Cancer Ther. 2014;13(1):101–11. PMID:24092811. doi:10.1158/1535-7163.MCT-13-0396.
   PubMed Web of Science ®Google Scholar
• Seifert O, Plappert A, Heidel N, Fellermeier S, Messerschmidt SKE, Richter F, Kontermann RE. The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity. Protein Eng Des Sel. 2012;25(10):603–12. PMID:22988132. doi:10.1093/protein/gzs059.
   PubMed Web of Science ®Google Scholar
• Hutt M, Marquardt L, Seifert O, Siegemund M, Müller I, Kulms D, Pfizenmaier K, Kontermann RE. Superior properties of Fc-comprising scTRAIL fusion proteins. Mol Cancer Ther. 2017;16(12):2792–802. PMID:28904131. doi:10.1158/1535-7163.MCT-17-0551.
   PubMed Web of Science ®Google Scholar
• Dong F, Gu J, Ghayur T. IgM- or IgE-Modified binding proteins and uses thereof. 2016. US 2018 / 0194861 A1.
   Google Scholar
• Fischer R, Sendetski M, Del Rivero T, Martinez GF, Bracchi-Ricard V, Swanson KA, Pruzinsky EK, Delguercio N, Rosalino MJ, Padutsch T, et al. TNFR2 promotes Treg-mediated recovery from neuropathic pain across sexes. Proc Natl Acad Sci U S A. 2019;116(34):17045–50. PMID:31391309. doi:10.1073/pnas.1902091116.
   PubMed Web of Science ®Google Scholar
• Seifert O, Rau A, Beha N, Richter F, Kontermann RE. Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules. MAbs. 2019;11(5):919–29. PMID:30951400. doi:10.1080/19420862.2019.1603024.
   PubMed Web of Science ®Google Scholar
• Wan T, Beavil RL, Fabiane SM, Beavil AJ, Sohi MK, Keown M, Young RJ, Henry AJ, Owens RJ, Gould HJ, et al. The crystal structure of IgE Fc reveals an asymmetrically bent conformation. Nat Immunol. 2002;3(7):681–86. PMID:12068291. doi:10.1038/ni811.
   PubMed Web of Science ®Google Scholar
• Kabat EA, Wu, TT, Perry, HH, Gottesman, KS, Foeller, C. Sequences of proteins of immunological interest. In: Bd, edition 5 (pp. 91–3242). NIH Publication; 1991.
   Google Scholar
• Martens T, Schmidt N-O, Eckerich C, Fillbrandt R, Merchant M, Schwall R, Westphal M, Lamszus K. A novel one-armed anti-c-met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res. 2006;12(20):6144–52. PMID:17062691. doi:10.1158/1078-0432.CCR-05-1418. PMID:17062691
   PubMed Web of Science ®Google Scholar
• Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, Huang A, Yang N, Nishimura M, Greve J, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A. 2013;110(32):E2987–96. PMID:23882082. doi:10.1073/pnas.1302725110.
   PubMed Web of Science ®Google Scholar
• Schmitt LC, Rau A, Seifert O, Honer J, Hutt M, Schmid S, Zantow J, Hust M, Dübel S, Olayioye MA, et al. Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV. MAbs. 2017;9(5):831–43. PMID:28421882. doi:10.1080/19420862.2017.1319023.
   PubMed Web of Science ®Google Scholar
• Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. An efficient route to human bispecific IgG. Nat Biotechnol. 1998;16(7):677–81. PMID:9661204. doi:10.1038/nbt0798-677.
   PubMed Web of Science ®Google Scholar
• Rivera J, Olivera A. A current understanding of Fc epsilon RI-dependent mast cell activation. Curr Allergy Asthma Rep. 2008;8(1):14–20. PMID:18377769. doi:10.1007/s11882-008-0004-z.
   PubMed Web of Science ®Google Scholar
• Sutton BJ, Davies AM, Bax HJ, Karagiannis SN. IgE antibodies: from structure to function and clinical translation. Antibodies (Basel). 2019;8(1):19. PMID:31544825. doi:10.3390/antib8010019.
   PubMedGoogle Scholar
• Cooke HA, Arndt J, Quan C, Shapiro RI, Wen D, Foley S, Vecchi MM, Preyer M. EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies. MAbs. 2018;10(8):1248–59. PMID:30215570. doi:10.1080/19420862.2018.1519631.
   PubMed Web of Science ®Google Scholar
• McDonnell JM, Calvert R, Beavil RL, Beavil AJ, Henry AJ, Sutton BJ, Gould HJ, Cowburn D. The structure of the IgE cepsilon2 domain and its role in stabilizing the complex with its high-affinity receptor Fcepsilonrialpha. Nat Struct Biol. 2001;8(5):437–41. PMID:11323720. doi:10.1038/87603.
   PubMedGoogle Scholar
• Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol. 2014;32(2):191–98. PMID:24463572. doi:10.1038/nbt.2797.
   PubMed Web of Science ®Google Scholar
• Wang C, Vemulapalli B, Cao M, Gadre D, Wang J, Hunter A, Wang X, Liu D. A systematic approach for analysis and characterization of mispairing in bispecific antibodies with asymmetric architecture. MAbs. 2018;10(8):1226–35. PMID:30153083. doi:10.1080/19420862.2018.1511198.
   PubMed Web of Science ®Google Scholar
• Wu X, Sereno AJ, Huang F, Zhang K, Batt M, Fitchett JR, He D, Rick HL, Conner EM, Demarest SJ. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies. MAbs. 2015;7(2):364–76. PMID:25611120. doi:10.1080/19420862.2015.1007826.
   PubMed Web of Science ®Google Scholar
• Digiammarino EL, Harlan JE, Walter KA, Ladror US, Edalji RP, Hutchins CW, Lake MR, Greischar AJ, Liu J, Ghayur T, et al. Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design. MAbs. 2011;3(5):487–94. PMID:21814039. doi:10.4161/mabs.3.5.16326.
   PubMed Web of Science ®Google Scholar
• Steinmetz A, Vallée F, Beil C, Lange C, Baurin N, Beninga J, Capdevila C, Corvey C, Dupuy A, Ferrari P, et al. CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications. MAbs. 2016;8(5):867–78. PMID:26984268. doi:10.1080/19420862.2016.1162932.
   PubMed Web of Science ®Google Scholar
• Slaga D, Ellerman D, Lombana TN, Vij R, Li J, Hristopoulos M, Clark R, Johnston J, Shelton A, Mai E, et al. Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3. Sci Transl Med. 2018;10(463). PMID:30333240. doi:10.1126/scitranslmed.aat5775.
   PubMed Web of Science ®Google Scholar
• Aschmoneit N, Steinlein S, Kühl L, Seifert O, Kontermann RE. A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells. Sci Rep. 2021;11(1):13880. PMID:34230555. doi:10.1038/s41598-021-93351-0.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Ramakrishnan B, Li J, Wang Y, Feng Y, Prabakaran P, Colantonio S, Dyba MA, Qasba PK, Dimitrov DS. Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar. MAbs. 2014;6(5):1190–200. PMID:25517304. doi:10.4161/mabs.29889.
   PubMed Web of Science ®Google Scholar
• Andreev J, Thambi N, Perez Bay AE, Delfino F, Martin J, Kelly MP, Kirshner JR, Rafique A, Kunz A, Nittoli T, et al. Bispecific antibodies and antibody-drug conjugates (ADCs) bridging HER2 and prolactin receptor improve efficacy of HER2 ADCs. Mol Cancer Ther. 2017;16(4):681–93. PMID:28108597. doi:10.1158/1535-7163.MCT-16-0658.
   PubMed Web of Science ®Google Scholar
• de GBECG, Vink T, ten NH, Breij ECW, Satijn D, Wubbolts R, Miao D, Pwhi P. Efficient payload delivery by a bispecific antibody-drug conjugate targeting HER2 and CD63. Mol Cancer Ther. 2016;15(11):2688–97. PMID:27559142. doi:10.1158/1535-7163.MCT-16-0364.
   PubMed Web of Science ®Google Scholar
• Takemoto H, Nishimura S, Kosada Y, Hata S, Takagi S, Hosoi S, Ezumi K, Ide M, Harada S. Anti-human IgE monoclonal antibodies recognizing epitopes related to the binding sites of high and low affinity IgE receptors. Microbiol Immunol. 1994;38(1):63–71. PMID:7519718. doi:10.1111/j.1348-0421.1994.tb01745.x.
   PubMed Web of Science ®Google Scholar
• Garman SC, Wurzburg BA, Tarchevskaya SS, Kinet JP, Jardetzky TS. Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha. Nature. 2000;406(6793):259–66. PMID:10917520. doi:10.1038/35018500.
   PubMed Web of Science ®Google Scholar
• Wurzburg BA, Jardetzky TS. Structural insights into the interactions between human IgE and its high affinity receptor FcepsilonRI. Mol Immunol. 2002;38(14):1063–72. PMID:11955598. doi:10.1016/s0161-5890(02)00035-4.
   PubMed Web of Science ®Google Scholar
• van Loghem E, Aalberse RC, Matsumoto H. A genetic marker of human IgE heavy chains, Em(1). Vox Sang. 1984;46(4):195–206. PMID:6201004. doi:10.1111/j.1423-0410.1984.tb00075.x.
   PubMed Web of Science ®Google Scholar